Trial Profile
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin in Obese and Overweight Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Metreleptin (Primary) ; Pramlintide (Primary)
- Indications Obesity; Overweight
- Focus Therapeutic Use
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 20 Mar 2014 New trial record